Zobrazeno 1 - 10
of 1 013
pro vyhledávání: '"Zwaveling J"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Verschueren MV; Department of Clinical Pharmacy, St Antonius Hospital, Utrecht, the Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Abedian Kalkhoran H; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Pharmacy, Haga Teaching Hospital, The Hague, the Netherlands., Deenen M; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands., van den Borne BEEM; Department of Respiratory Medicine, Catharina Hospital, Eindhoven, the Netherlands., Zwaveling J; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Visser LE; Department of Pharmacy, Haga Teaching Hospital, The Hague, the Netherlands.; Department of Hospital Pharmacy, Erasmus Medical Centre, Rotterdam, the Netherlands.; Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands., Bloem LT; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Peters BJM; Department of Clinical Pharmacy, St Antonius Hospital, Utrecht, the Netherlands., van de Garde EMW; Department of Clinical Pharmacy, St Antonius Hospital, Utrecht, the Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Publikováno v:
JCO clinical cancer informatics [JCO Clin Cancer Inform] 2024 Oct; Vol. 8, pp. e2400053. Date of Electronic Publication: 2024 Oct 04.
Autor:
Grit GF; Dutch Institute for Clinical Auditing, Leiden, the Netherlands; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: g.f.grit@umcg.nl., van Geffen E; LOGEX Healthcare Analytics, Amsterdam, the Netherlands., Malmberg R; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van Leeuwen R; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Böhringer S; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands., Jm Smit H; Department of Pulmonary Medicine, Rijnstate Hospital, Arnhem, the Netherlands., Brocken P; Department of Pulmonology, HAGA Teaching Hospital, Den Haag, the Netherlands., Fh Eijsink J; Department of Clinical Pharmacy, Isala Klinieken, Zwolle, the Netherlands., Dronkers E; LOGEX Healthcare Analytics, Amsterdam, the Netherlands., Gal P; LOGEX Healthcare Analytics, Amsterdam, the Netherlands., Jaarsma E; LOGEX Healthcare Analytics, Amsterdam, the Netherlands., Jhm van Drie-Pierik R; Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, the Netherlands., Mp Eldering-Heldens A; Department of Pharmacy, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands., Machteld Wymenga AN; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands., Gm Mol P; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands., Zwaveling J; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Hilarius D; Department of Pharmacy, Rode Kruis Ziekenhuis, Beverwijk, the Netherlands.
Publikováno v:
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Oct; Vol. 196, pp. 107950. Date of Electronic Publication: 2024 Aug 30.
Autor:
Moes DJAR; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. D.J.A.R.Moes@lumc.nl., Hendrikx JJMA; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute (NKI-AVL), Amsterdam, The Netherlands., Guchelaar HJ; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Bakker JL; Department of Medical Oncology, Amphia Hospital, Breda, The Netherlands., Dezentjé VO; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Rouw N; Department of Clinical Pharmacy, Amphia Hospital, Breda, The Netherlands.; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., van Erp NP; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Smit EF; Department of Pulmonology, Leiden University Medical Centre, Leiden, The Netherlands., van den Heuvel MM; Department of Pulmonology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Munnink THO; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands., van Kats M; Division of Medical Oncology, Department of Internal Medicine M. van Kats, Maastricht University Medical Center Maastricht, Maastricht, The Netherlands., Croes S; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center Maastricht, Maastricht, The Netherlands., Kroep JR; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Zwaveling J; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., Ter Heine R; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Publikováno v:
Targeted oncology [Target Oncol] 2024 Sep; Vol. 19 (5), pp. 789-796. Date of Electronic Publication: 2024 Jun 18.
Autor:
Laar, S.A. van, Gombert-Handoko, K.B., Wassenaar, S., Kroep, J.R., Guchelaar, H.J., Zwaveling, J.
Publikováno v:
Supportive Care in Cancer. SPRINGER
Supportive Care in Cancer
Supportive Care in Cancer
Purpose Chemotherapy-induced febrile neutropenia (FN) is a life-threatening and chemotherapy dose-limiting adverse event. FN can be prevented with granulocyte-colony stimulating factors (G-CSFs). Guidelines recommend primary G-CSF use for patients re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e17a1ed5d016bb4b1d587ffa3028ce65
https://hdl.handle.net/1887/3458839
https://hdl.handle.net/1887/3458839
Autor:
ten Brink, M.H., Zwaveling, J., Swen, J.J., Bredius, R.G.M., Lankester, A.C., Guchelaar, H.J.
Publikováno v:
In Drug Discovery Today October 2014 19(10):1572-1586
Autor:
van der Stoep MYEC; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands; Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: e.vanderstoep@lumc.nl., Bense JE; Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands., de Kloet LC; Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands., von Asmuth EGJ; Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands., de Pagter APJ; Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands., Hannema SE; Department of Pediatrics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Zwaveling J; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Lankester AC; Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Publikováno v:
Transplantation and cellular therapy [Transplant Cell Ther] 2023 Aug; Vol. 29 (8), pp. 529.e1-529.e5. Date of Electronic Publication: 2023 May 06.
Autor:
van Laar SA; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, The Netherlands., Gombert-Handoko KB; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, The Netherlands., Wassenaar S; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, The Netherlands., Kroep JR; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, The Netherlands., Zwaveling J; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, The Netherlands. j.zwaveling@lumc.nl.
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2022 Nov; Vol. 30 (11), pp. 9181-9189. Date of Electronic Publication: 2022 Aug 31.
Autor:
Laar, S.A. van, Gombert-Handoko, K.B., Groenwold, R.H.H., Hulle, T. van der, Visser, L.E., Houtsma, D., Guchelaar, H.J., Zwaveling, J.
Publikováno v:
Frontiers in Pharmacology, 13:803935. Frontiers Media S.A.
Frontiers in Pharmacology, 13. FRONTIERS MEDIA SA
Frontiers in Pharmacology, 13. FRONTIERS MEDIA SA
The number of treatment options for patients with metastatic renal cell carcinoma (mRCC) has significantly grown in the last 15 years. Although randomized controlled trials are fundamental in investigating mRCC treatment efficacy, their external vali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aee42fd5ccb2bcc58a3443136ade56ec
https://pure.eur.nl/en/publications/ad275f61-f06e-4688-a5bd-f126a103df9f
https://pure.eur.nl/en/publications/ad275f61-f06e-4688-a5bd-f126a103df9f
Autor:
Stoep, M.Y.E.C. van der, Oostenbrink, L.V.E., Bredius, R.G.M., Moes, D.J.A.R., Guchelaar, H.J., Zwaveling, J., Lankester, A.C.
Publikováno v:
Frontiers in Pharmacology, 13. FRONTIERS MEDIA SA
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established curative treatment that has significantly improved clinical outcome of pediatric patients with malignant and non-malignant disorders. This is partly because of the use of saf